CNN put this up ?

Once considered a more underground activity, marijuana has become increasingly popular over the years, resulting in legalisation to grow, sell and smoke it in states like Colorado and Washington. Cannabis has become one of the most controversial topics in America, but just decades ago it was a legitimate medication on U.S. formulary. No matter the circumstance, the debate over marijuana still exists and one question remains the same: is marijuana bad for you or, could it actually be good for you?

6 Replies

oldestnewest
  • There is some interesting research going on with liver and cbds thc , extracts , it worked for me , so I think it really worth looking at , shame it still illegal in the uk , I thinking of moving to France it legal there , I Ireland is about to rewrite the law book on this ,, I only two hours from France so I can still see my family and granddaughter at the week ends , just the hassle and cost of the travel and the energy , And time ,, but better that then ending up in jail and I would not like my granddaughter seeing me in jail it would up set her she only 3'1/2.' And even then the problem still would not end as with out my illegal in the uk medicine , I get sick , and maybe die , why , I not a threat to any body , if there is no victims how can there be a crime ? And what evidence is there to ban this plant , from my small research it just seems to do good , not bad , ? I lived in fear of cancer Nd my hepc now I am well I live in fear of the law www.confused .com

  • Marajuana is dangerous for those with any liver issue or people who are immunosuppressed because there is a particular type of mold that can grow in it and make someone like us very very sick. Not worth the risk in my opinion.

  • That's why you don't get weed with mold in it. What you want is the cannabis oil extract. That way you are ingesting the cannabinoids without the need to smoke it. You can smoke the oil, but ingesting it is more effective. High concentrations of CBD oil will help with many diseases and helps boost normal cell productivity while inhibiting metastatic behavior of diseased/infected cells.

  • I do agree it best not to take any thing in side the body with mould on ,do you have any data on this ,or is this just one of those fact on this plant that is just made up to scare people ,would like to see where this documented , so we can deal,with it ,

    I have some interesting latest data on cannibis and livers , I think they was using the mould free cannibis ,do you know the name of this mould or is it just any old mould , mouldy old dope , lol

  • Use Of Cannabidiol (CBD) In The Treatment Of Hepatitis

    Oct 05 Posted by Brad Mossman

    Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as Δ9-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.

    Claims

    1. A method of treating hepatitis in a subject, the method comprising:identifying a subject suffering from or at risk for hepatitis; andadministering cannabidiol to the subject; wherein said cannabidiol is synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids.

    2. A method as in claim 1, wherein said cannabidiol is administered to the subject substantially free of any psychotropic agent.

    3. A method as in claim 1, wherein said cannabidiol is administered to the subject substantially free of Δ9-tetrahydrocannabinol.

    4. A method as in claim 1 further comprising providing said cannabidiol in a drug delivery vehicle.

    5. A method as in claim 4, wherein the drug delivery vehicle is a sustained release drug delivery vehicle.

    6. A method as in claim 1, wherein the method is an in vivo therapeutic or prophylactic treatment method.

    7. A method as in claim 1, wherein said cannabidiol is injected into the subject.

    8. A method as in claim 1, wherein the subject is suffering from autoimmune hepatitis.

    9. A method for inducing apoptosis of thymocytes in a subject, the method comprising administering to a subject an amount of cannabidiol greater than about 100 milligrams cannabidiol per kilogram mass of the subject, said cannabidiol being synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids, wherein upon administration of said cannabidiol, thymic cellularity of said subject decreases.

    10. A method as in claim 9, wherein said cannabidiol is administered to the subject substantially free of any psychotropic agent.

    11. A method as in claim 9, wherein said cannabidiol is administered to the subject substantially free of Δ9-tetrahydrocannabinol.

    12. A method as in claim 9 further comprising providing said cannabidiol in a drug delivery vehicle.

    13. A method as in claim 12, wherein the drug delivery vehicle is a sustained release drug delivery vehicle.

    14. A method as in claim 9, wherein the method is an in vivo therapeutic or prophylactic treatment method.

    15. A method as in claim 9, wherein said cannabidiol is injected into the subject.

    16. A method as in claim 9, wherein the subject is suffering from autoimmune hepatitis.

    17. A method for inducing apoptosis of splenocytes in a subject, the method comprising administering to a subject an amount of cannabidiol greater than about 50 milligrams cannabidiol per kilogram mass of the subject; said cannabidiol being synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids, wherein upon administration of said cannabidiol, splenic cellularity of said subject decreases.

    18. A method as in claim 17, wherein said cannabidiol is administered to the subject substantially free of any psychotropic agent.

    19. A method as in claim 17, wherein said cannabidiol is administered to the subject substantially free of Δ9-tetrahydrocannabinol.

    20. A method as in claim 17 further comprising providing said cannabidiol in a drug delivery vehicle.

    21. A method as in claim 20, wherein the drug delivery vehicle is a sustained release drug delivery vehicle.

    22. A method as in claim 17, wherein the method is an in vivo therapeutic or prophylactic treatment method.

    23. A method as in claim 17, wherein said cannabidiol is injected into the subject.

    24. A method as in claim 17, wherein the subject is suffering from autoimmune hepatitis.

    25. A method for decreasing the level of plasma aspartate transaminase in a subject, the method comprising administering cannabidiol to a subject exhibiting elevated levels of plasma aspartate transaminase, said cannabidiol being synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids, wherein following administration of said cannabidiol, the subject's level of plasma aspartate transaminase decreases.

    26. A method as in claim 25, wherein said cannabidiol is administered to the subject substantially free of any psychotropic agent.

    27. A method as in claim 25, wherein said cannabidiol is administered to the subject substantially free of Δ9-tetrahydrocannabinol.

    28. A method as in claim 25 further comprising providing said cannabidiol in a drug delivery vehicle.

    29. A method as in claim 28, wherein the drug delivery vehicle is a sustained release drug delivery vehicle.

    30. A method as in claim 25, wherein the method is an in vivo therapeutic or prophylactic treatment method.

    31. A method as in claim 25, wherein said cannabidiol is injected into the subject.

    32. A method as in claim 25, wherein the subject is suffering from autoimmune hepatitis.

    33. A method as in claim 25, wherein the cannabidiol is administered to ysaid subject in an amount greater than about 50 milligrams cannabidiol per kilogram mass of the subject.

  • I think your see that body of early evidence is becoming very strong in favour of cannibis based medicines , so for me it very important to separate myth from fact , or facts ,,and at the end of the day it more about having the right to safe herbal treatment, and cannabis has no know overdoses accredited to her , it's just at the moment for me having been through the chemo cross one year , it was the last thing left !,I tried it and it worked , so I owe my life to it , thank you for your post ,,

You may also like...